{
    "symbol": "MESO",
    "quarter": 4,
    "year": 2022,
    "date": "2022-08-30 22:28:02",
    "content": " More recent data published in bone marrow transplantation last year in a controlled trial performed by lead investigators at Mount Sinai Hospital in New York, showed that when children from our Phase 3 program were matched by disease severity with control patients receiving the best available care, the day 28 response levels in those with MAP scores above 0.29, a validated biomarker of high risk patient population demonstrated a significant benefit in both day 28 response and Remestemcel treated patients on the left, 67% versus 10%."
}